.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The development of Procizumab in shock management represents a significant milestone in treating refractory circulatory failure. Dipeptidyl peptidase 3 (DPP3) is primarily an intracellular protein involved in antioxidant responses. However, acute tissue damage causes the release of this protein into the bloodstream. This circulating form (cDPP3) acts as a cardiac depression factor. Consequently, it degrades angiotensin II, which is essential for maintaining vascular tone. This enzymatic process leads to rapid hemodynamic collapse and multi-organ dysfunction.
Researchers developed Procizumab (invobenitug) to neutralize this pathological driver. Specifically, it is a humanized IgG1 kappa monoclonal antibody that binds human cDPP3 with high affinity. The initial murine variant was generated by immunizing mice with a DPP3-derived peptide. Subsequently, the antibody was humanized through complementarity-determining region (CDR) grafting. Furthermore, the final recombinant antibody is produced in Chinese hamster ovary cells. Importantly, it lacks Fc-mediated effector functions, which minimizes the risk of unwanted immune responses like cell-mediated toxicity.
Non-clinical studies have validated the efficacy of this approach. In cardiac dysfunction models, the antibody successfully inhibited cDPP3 activity and improved hemodynamic parameters. Additionally, pharmacokinetic analyses in rats showed a favorable tissue distribution. Currently, researchers are evaluating the antibody in the PROCARD clinical trial series. This first-in-class therapy aims to move beyond supportive care by addressing the biological root of shock. Therefore, it could significantly reduce the high mortality rates associated with cardiogenic and septic shock.
Procizumab neutralizes circulating DPP3 (cDPP3) to prevent the degradation of angiotensin II. This action helps restore RAAS balance and stabilizes cardiovascular function during acute shock.
When cDPP3 enters the circulation due to cell death, it destroys peptides that regulate heart and kidney function. High levels of this enzyme are strong predictors of short-term mortality and organ failure.
Studies confirmed that Procizumab lacks Fc-mediated immune effector functions, such as phagocytosis or complement-dependent toxicity. This ensures the antibody neutralizes the target without causing broader immune-mediated damage.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider for any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Genest M et al. Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3. MAbs. 2026 Dec undefined. doi: 10.1080/19420862.2026.2675077. PMID: 42165222.
Deniau B, Blet A, Santos K, et al. Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury. PMC. 2024.
4TEEN4 Pharmaceuticals. 4TEEN4 begins trial of antibody therapy for cardiogenic shock. PharmaTimes. 2025.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Procizumab is a humanized antibody that neutralizes circulating DPP3, a biological driver of shock, by preventing angiotensin II degradation....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
